Clinical trial · Interventional
Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma
A Trial of Metronomic Chemotherapy With Tegafur/Uracil for Patients With Locally Advanced (Stage III~IVB) Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT00855881CI-TRIAL-00005287unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It is the investigators understanding that the combination of clinical trial with laboratory cellular/molecular assay is relevant to the current promising mainstream, the translational research. The design of this trial fulfills this concept and would be a good example conducting in Mackay Memorial hospital.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| tegafur-uracil | Drug | Tegafur | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment arm
- description
- Treated with tegafur-uracil for 1 year
- interventionNames
- Drug: tegafur-uracil
Primary outcomes (1)
- measure
- 2-year RFS
- timeFrame
- 6 years
Secondary outcomes (1)
- measure
- Overall survival
- timeFrame
- 8 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed non-nasopharyngeal head and neck squamous cell carcinoma * Complete response(CR) to previous treatment * White blood cell (WBC) count greater than 3,000/mm3 and absolute neutrophil count (ANC) greater than 1,500/mm3, and platelets greater than 50,000/mm3 * Serum bilirubin less than 2 times the upper limit of normal range (ULN) * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) * Serum creatinine less than 2.0 times the ULN * ECOG performance status 0, 1, 2 * Age, 20 years or older Exclusion Criteria: * Other malignancy, with the exception of curatively treated non-melanoma skin cancer or cervical carcinoma in situ prior to commencement of the study * CR was confirmed more than 6 weeks prior to commencement of the study * Concurrent treatment which may interfere with evaluation * Pregnancy or breast feeding
References
Publications (0)
Data not yet available
No reference posted for this study.